356 related articles for article (PubMed ID: 28209511)
1. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway.
Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J
Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511
[TBL] [Abstract][Full Text] [Related]
2. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
[TBL] [Abstract][Full Text] [Related]
3. Heparanase regulates levels of syndecan-1 in the nucleus.
Chen L; Sanderson RD
PLoS One; 2009; 4(3):e4947. PubMed ID: 19305494
[TBL] [Abstract][Full Text] [Related]
4. Alteration of endothelial proteoglycan and heparanase gene expression by high glucose, insulin and heparin.
Han J; Hiebert LM
Vascul Pharmacol; 2013; 59(3-4):112-8. PubMed ID: 23939434
[TBL] [Abstract][Full Text] [Related]
5. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
Yang Y; Macleod V; Miao HQ; Theus A; Zhan F; Shaughnessy JD; Sawyer J; Li JP; Zcharia E; Vlodavsky I; Sanderson RD
J Biol Chem; 2007 May; 282(18):13326-33. PubMed ID: 17347152
[TBL] [Abstract][Full Text] [Related]
6. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.
Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD
FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281
[TBL] [Abstract][Full Text] [Related]
7. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
9. Heparanase-Regulated Syndecan-1 Shedding Facilitates Herpes Simplex Virus 1 Egress.
Hadigal S; Koganti R; Yadavalli T; Agelidis A; Suryawanshi R; Shukla D
J Virol; 2020 Feb; 94(6):. PubMed ID: 31827001
[TBL] [Abstract][Full Text] [Related]
10. Biology of the Heparanase-Heparan Sulfate Axis and Its Role in Disease Pathogenesis.
Vlodavsky I; Barash U; Nguyen HM; Yang SM; Ilan N
Semin Thromb Hemost; 2021 Apr; 47(3):240-253. PubMed ID: 33794549
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1.
Hollósi P; Váncza L; Karászi K; Dobos K; Péterfia B; Tátrai E; Tátrai P; Szarvas T; Paku S; Szilák L; Kovalszky I
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 32977498
[TBL] [Abstract][Full Text] [Related]
12. Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells.
Charni F; Friand V; Haddad O; Hlawaty H; Martin L; Vassy R; Oudar O; Gattegno L; Charnaux N; Sutton A
Biochim Biophys Acta; 2009 Oct; 1790(10):1314-26. PubMed ID: 19632304
[TBL] [Abstract][Full Text] [Related]
13. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.
Joyce JA; Freeman C; Meyer-Morse N; Parish CR; Hanahan D
Oncogene; 2005 Jun; 24(25):4037-51. PubMed ID: 15806157
[TBL] [Abstract][Full Text] [Related]
14. A critical role for lymphatic endothelial heparan sulfate in lymph node metastasis.
Yin X; Truty J; Lawrence R; Johns SC; Srinivasan RS; Handel TM; Fuster MM
Mol Cancer; 2010 Dec; 9():316. PubMed ID: 21172016
[TBL] [Abstract][Full Text] [Related]
15. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis.
Cohen-Kaplan V; Naroditsky I; Zetser A; Ilan N; Vlodavsky I; Doweck I
Int J Cancer; 2008 Dec; 123(11):2566-73. PubMed ID: 18798279
[TBL] [Abstract][Full Text] [Related]
16. Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells.
Masola V; Gambaro G; Tibaldi E; Onisto M; Abaterusso C; Lupo A
Biochim Biophys Acta; 2011 Aug; 1813(8):1475-82. PubMed ID: 21600934
[TBL] [Abstract][Full Text] [Related]
17. Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression.
Rangarajan S; Richter JR; Richter RP; Bandari SK; Tripathi K; Vlodavsky I; Sanderson RD
J Histochem Cytochem; 2020 Dec; 68(12):823-840. PubMed ID: 32623935
[TBL] [Abstract][Full Text] [Related]
18. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
[TBL] [Abstract][Full Text] [Related]
19. Heparanase induces tissue factor pathway inhibitor expression and extracellular accumulation in endothelial and tumor cells.
Nadir Y; Brenner B; Gingis-Velitski S; Levy-Adam F; Ilan N; Zcharia E; Nadir E; Vlodavsky I
Thromb Haemost; 2008 Jan; 99(1):133-41. PubMed ID: 18217145
[TBL] [Abstract][Full Text] [Related]
20. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype.
Purushothaman A; Hurst DR; Pisano C; Mizumoto S; Sugahara K; Sanderson RD
J Biol Chem; 2011 Sep; 286(35):30377-30383. PubMed ID: 21757697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
